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Abstract 
The use of adherent monolayer cultures have produced many insights into melanoma cell 
growth and differentiation, but often novel therapeutics demonstrated to act on these cells are 
not active in vivo.  It is imperative that new methods of growing melanoma cells that reflect 
growth in vivo are investigated.  To this end, a range of human melanoma cell lines passaged 
as adherent cultures or induced to form melanoma spheres (melanospheres) in stem cell 
media have been studied to compare cellular characteristics and protein expression. 
Melanoma spheres and tumours grown from cell lines as mouse xenografts had increased 
heterogeneity when compared to adherent cells and 3D-spheroids in agar (aggregates).  
Furthermore, cells within the melanoma spheres and mouse xenografts each displayed a high 
level of reciprocal BRN2 or MITF expression, which matched more closely the pattern seen 
in human melanoma tumours in situ, rather than the propensity for co-expression of these 
important melanocytic transcription factors seen in adherent cells and 3D-spheroids.  
Notably, when the levels of the BRN2 and MITF proteins were each independently repressed 
using siRNA treatment of adherent melanoma cells, members of the NOTCH pathway 
responded by decreasing or increasing expression respectively.  This links BRN2 as an 
activator and conversely MITF as a repressor of the NOTCH pathway in melanoma cells.  
Loss of the BRN2-MITF axis in antisense ablated cell lines decreased melanoma sphere 
forming capability, cell adhesion during 3D-spheroid formation, and invasion through a 
collagen matrix.  Combined, this evidence suggests that the melanoma sphere culture system 
induces subpopulations of cells that may more accurately portray the in vivo disease, than 
growth as adherent melanoma cells.  
Key words: cell adhesion, invasion, melanoma, metastasis, NOTCH, transcription factor 
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Introduction 
Despite several decades of research on the causes and potential treatments for melanoma, 
little improvement has been made in the prognosis of this cancer which remains at less than 
15% survival after 5 yrs for patients diagnosed with metastatic disease (Miller and Mihm, 
2006).  One issue slowing progress is the large disparity that often exists between 
experimental results and clinical outcomes.  In order to screen new therapeutic drugs more 
quickly and cost effectively new culture models representative of the clinical setting are 
needed.  This has lead to a gain in popularity of three-dimensional (3D) culture systems as an 
alternative to adherent monolayer culture.  Fang et. al. 2005 demonstrated that growth of 
melanoma cell lines in stem cell media to form non-adherent spheres increased their 
tumorigenic grafting ability, making this an interesting new model to study (Fang et al., 
2005).  Growth of melanoma spheres was initially developed because it was thought that the 
stem cell conditions would enrich an otherwise small ‘cancer stem cell’ population (Schatton 
et al., 2008).  However, recent evidence has dispelled the notion of only a select 
subpopulation of cancer cells having the ability to form a melanoma tumour (Quintana et al., 
2008), making it likely that other unknown factors are responsible for the increased 
tumorigenesis seen with melanoma sphere formation and growth. As yet, the relationship 
between the sphere growth characteristics, expression profiles and behaviour in relation to 
melanoma in situ has not been fully investigated. 
An important consideration in melanoma treatment is the high degree of heterogeneity found 
in tumours (Hoek et al., 2008), as clearly illustrated by the inverse expression pattern of two 
transcription factors, BRN2 and MITF, important in proliferation and metastasis (Carreira et 
al., 2006; Goodall et al., 2008).  These two proteins have been implicated in the regulation of 
downstream pathways linked to invasive abilities, as has the NOTCH pathway (Pinnix and 
Herlyn, 2007), but as yet a relationship between these pathways has not been described.  In 
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human melanoma tumour samples BRN2 and MITF mark two distinct subpopulations 
predicted to have different proliferative and invasive abilities, while in adherent cultures they 
are seen to be co-expressed.  Therefore, the pattern of these two proteins may provide a 
measure of tumour-like heterogeneity seen using in vitro culture systems and have been 
investigated here using adherent and non-attached melanoma cell growth states. 
Results 
 
Media conditions required for melanoma sphere formation 
A range of diverse melanoma cell lines including those of known BRAF, NRAS, PTEN gene 
mutation status (Johansson et al., 2007; Pavey et al., 2004), several with β-catenin mutations, 
non-pigmented and pigmented strains, four ocular melanomas, and a cell line showing 
spontaneous sphere growth were available for this study.  In all, 31 parental melanoma cell 
lines (Supplementary Table 1) and several primary melanoblast strains (Cook et al., 2003) 
were investigated for their ability to form spheres in 3 different types of media using the 
method first developed by Fang et al. 2005 (Fang et al., 2005).  This method utilized stem 
cell growth conditions with mouse embryo fribroblast (MEF) conditioned media to promote 
the growth of non-adherent spheres.  In addition to standard melanoma (MEL) and stem cell 
media (hESCM-KSR), we also assayed for sphere growth in stem cell media supplemented 
with 10% FBS (hESCM-FBS) instead of 20% Knockout Serum Replacement.  
Cells were allowed to grow undisturbed in each media for 14 days or until melanoma spheres 
formed.  Melanoblasts were unable to sustain growth in any of these media.  Of the 
melanoma cell lines tested only 16% had the capacity for detached cell growth using MEL 
media with only a minor increase to 19% seen using hESCM-FBS; however the majority of 
cell lines, 87% (27 out of 31), were capable of forming non-adherent melanoma spheres 
when cultured in hESCM-KSR.  Morphological differences between cell lines were observed 
during initial sphere formation.  Some lines produced small spheres within the first few days 
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of culture, while others grew large sheets of cells detaching after 14 days of culture.  Two 
examples showing some of the variation in sphere formation are illustrated using the 
pigmented A11 (Figure 1A) and the spontaneous sphere forming D10 (Figure 1B) cell lines.  
Melanoma spheres were harvested and passaged by dissociation into single cell suspensions 
and replated.  After passaging, the melanoma spheres tended to be smaller and to have a 
more regular globular shape.  In agreement with previous data (Fang et al., 2005), some cell 
lines lost pigmentation during the first few passages in hESCM-KSR media.  The A11 cells 
were initially darkly pigmented when cultured as an adherent monolayer in MEL media and 
became unpigmented after three serial passages as detached cells in hESCM-KSR media 
(Figure 1C).  Unpigmented sphere cells did not regain pigmentation after culturing as an 
adherent monolayer for 14 days in MEL media.  In contrast this change in pigmentation 
pattern was not seen in A11 melanoma spheres derived using hESCM-FBS media.  
Due to the greater success of sphere formation in hESCM-KSR media, only melanoma 
spheres generated under these conditions were used for further characterization.  To examine 
changes in protein profiles, we chose to focus our studies on three melanoma cell lines, two 
BRAF V600E positive cell lines, previously studied extensively in our laboratory, A2058 
and MM96L, and one additional pigmented melanoma cell line, A11 expressing a mutant β-
catenin protein.  All three lines readily formed melanoma spheres. 
Regulatory protein changes between adherent and melanoma sphere cultures 
Previously, melanoma spheres were shown to establish tumours more readily in a mouse 
xenograft model than melanoma cells from adherent cultures (Fang et al., 2005).  Since we 
have previously shown that ablation of BRN2 gene expression prevents establishment of 
melanoma tumour growth in mouse xenografts (Thomson et al., 1995), we were interested to 
compare BRN2 protein levels in the same cell line under adherent versus melanoma sphere 
conditions in addition to other transcription factors known to be associated with melanoma 
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progression.  Western blot analysis of total protein extracts prepared from each cells grown 
adherently or as spheres demonstrated a consistent decrease in the level of BRN2 protein in 
melanoma spheres generated using all 3 cell lines A2058, A11, and MM96L (Figure 2A).  As 
BRN2 is proposed to repress MITF (Goodall et al., 2008) and induce NOTCH1 (Castro et 
al., 2006), two potential BRN2 downstream transcription factor targets, we also determined 
their expression.  Both MITF and NOTCH1 protein levels consistently decreased in spheres 
from all 3 melanoma lines when compared to their adherent counterpart (Figure 2A).  There 
was a similar suppression of the NOTCH ligands DLL1 and JAG2 during melanoma sphere 
growth. 
Assaying of RNA transcript levels in the adherent and melanoma spheres was performed 
using quantitative RT-PCR as shown by the representative data presented for the MM96L 
cell line (Figure 2B).  This revealed significant reductions in mRNA levels for BRN2, MITF, 
NOTCH1 and DLL1 in line with the reduction in their protein levels.  There was 
inconsistency between the protein and mRNA responses seen for JAG2, with a decrease in 
protein but not transcript in MM96L spheres.  Notably spheroid growth did not alter the 
transcript level of the ABCB5 gene, which had previously been described as a cancer 
initiating cell marker (Schatton et al., 2008).  
Given the cell heterogeneity found in melanoma, we were interested to examine the protein 
expression and localization at a cellular level of several of these proteins using 
immunofluorescence as well as measuring total protein levels.  Cryosections of melanoma 
spheres were stained and imaged along with matched adherent melanoma cells for 
comparison.  Immunofluoresence microscopy of the three NOTCH pathway proteins seen to 
be consistently reduced in levels by immunonoblot assay when A2058 cells were grown as 
melanospheres compared to adherent conditions was undertaken.  Adherent cells had strong 
and homogeneous intracellular cytoplasmic staining patterns for NOTCH1, JAG2 and DLL1 
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when counterstained with DAPI to highlight the nucleus (Figure 2C).  In contrast in the 
sections prepared from the fixed spheres there was substantially reduced JAG2 signal but no 
difference in cellular localisation.  For NOTCH1 and DLL1 there was diffuse staining in the 
cytoplasm, with no nuclear staining as seen by the blue colour of the DAPI stain.  Areas of 
stronger and weaker staining intensity were apparent in sections with the cells near the 
exterior of the sphere tending toward greater expression than those in the middle, but no 
conclusions could be drawn from the appearance of this distribution, apart from an increased 
heterogeneity compared to adherent cell growth.  
Immunofluorescence microscopy detects reciprocal BRN2 and MITF expression patterns in 
melanoma spheres and in tumour xenografts 
BRN2 and MITF transcription factors have been shown to have different expression patterns 
in adherent cultures as compared to in vivo tumour samples where they have been reported to 
mark two distinct subpopulations in melanoma biopsies (Carreira et al., 2006; Goodall et al., 
2008).  For this reason we investigated the expression patterns of these two transcription 
factors in melanoma spheres. Firstly, examination of adherent cultures of A2058, A11 and 
MM96L cells costained with anti-BRN2 (red) and anti-MITF antisera (green) by 
immunofluorescence confirmed that the majority of cells showed a high degree of BRN2-
MITF co-expression in the nucleus (colour range yellow to orange, Figure 3) with only a few 
cells that did not stain with anti-MITF antibody to some degree and no cells lacked BRN2 
expression when examined by single channel excitation (data not shown).   However, there 
were a minor number of isolated cells that stained principally with one or the other of these 
antibodies, appearing predominantly tinged red or green (Figure 3A upper panel).   Secondly, 
costaining of each of these melanoma cell lines when induced to adhere to each other and 
form a short term 3D spheroid aggregate structure through plating on a non-adherent agar 
covered tissue culture dish, produced spheres with a predominantly yellow 
immunofluorescent staining pattern (Figure 3A middle panel).  Lastly, in contrast to the 
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predominant co-expressed staining patterns of BRN2-MITF in the adherent and 3D spheroid 
aggregate states, melanoma spheres generated from the A2058, A11 and MM96L cell lines 
all revealed greater levels of heterogeneity and an appearance of reciprocal expression of 
BRN2 and MITF, with a predominance of cell nuclei being either red or green (Figure 3A 
lower panel). 
To compare the inverse BRN2-MITF immunofluorescent staining pattern obtained using 
sectioned melanoma spheres with that of melanoma cells grown as tumours in vivo, we 
sectioned and co-stained melanoma tissue from mouse xenografts (Figure 3B) and human 
superficial spreading melanoma (Figure 3C).  Two metastatic melanoma cell lines WM3734 
and WM115 grown either under adherent culture conditions or as melanoma spheres were 
injected into the dorsal area of immunocompromised mice and allowed to form tumours.  The 
initial culture conditions of either of these cell lines made no difference to the histological 
appearance seen upon H&E staining of the tumour sections.  Moreover, a dichotomous red-
green staining pattern of nuclei indicating either BRN2 positive or MITF positive 
subpopulations of cells was readily apparent in the melanoma tissue derived from both 
adherent and melanoma sphere derived xenografts.  There were surprisingly few cells in 
these sections giving rise to a yellow costaining signal in nuclei, indicating only a minor 
component of BRN2-MITF co-expression in the melanoma xenografts, but this did vary 
slightly between sections being inspected.  Of note was the absence of staining within some 
patches of cells when comparing consecutive sections prepared for H&E or 
immunofluoresence analysis.  This may represent regions of cell necrosis, another 
subpopulation of BRN2 and MITF negative melanoma cells, or another non-melanoma cell 
infiltrating or supporting the tumour.  Examination of human tumour sections was largely 
consistent with the predominant red or green nuclei staining pattern of the xenografts, 
however a slightly increased frequency of yellow nuclei was visible as seen in the 
highlighted box (Figure 3C).  
9 
The major conclusion to be drawn from the immunofluorescent analysis of BRN2-MITF co-
stained melanoma tumour sections is that there is a pattern of co-localization of BRN2 and 
MITF in some areas as well as restricted expression of sub populations as shown by Goodall 
and colleagues (Goodall et al., 2008).   
Repression of BRN2 or MITF shows reciprocal effects on NOTCH pathway members 
To determine if direct repression of the BRN2 transcription factor in melanoma cells would 
influence the mRNA expression of the NOTCH pathway ligand and receptors, the MM96L 
and A2058 cell lines grown in adherent conditions were treated with non-specific or BRN2 
targeted siRNA molecules.  Knockdown of the BRN2 protein in melanoma cells using this 
reagent has previously been demonstrated (Cook et al., 2005), and repression was confirmed 
by a decrease in total RNA quantitative RT-PCR (Figure 4A and B) and protein (Figure 4C) 
levels.  Notably, assay of the NOTCH1, JAG2 and DLL1 transcripts all showed a significant 
reduction of expression relative to the non-specific siRNA, concomitant with the knockdown 
of BRN2 in A2058 cells, and in MM96L cell extracts although the JAG2 transcript level was 
not altered the protein itself was reduced.  In contrast ABCB5 transcript levels were shown to 
increase upon BRN2 siRNA treatment of both cell lines.  For MITF, the transcript level was 
slightly reduced or unaltered upon BRN2 ablation, while the MITF protein appeared to 
increase in A2058 cell extracts, a result consistent with that reported previously (Cook and 
Sturm, 2008; Goodall et al., 2008) as BRN2 is known to act to repress MITF expression.  
Conducting the reverse experiment with an siRNA to the MITF transcription factor (Newton 
et al., 2007), confirmed repression of MITF mRNA and demonstrated a significant 2 fold or 
greater increase of BRN2, NOTCH1, JAG2 transcript levels, with a decrease in ABCB5 as 
did DLL1 in A2058 cells (Figure 4A and B).  The protein levels for BRN2 and NOTCH1 
were increased in both cell lines, as was JAG2 in A2058 cell extracts (Figure 4C).   
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The reciprocal effects of individually repressing these two transcription factors supports the 
hypothesis (Cook and Sturm, 2008) of opposing regulatory networks operating through these 
two proteins in melanoma cells both on their own expression (Carreira et al., 2006; Goodall 
et al., 2008; Thomson et al., 1995), and as demonstrated here on three members of the 
NOTCH pathway. 
Loss of BRN2-MITF expression compromises melanoma sphere formation and growth 
To assess the role of the BRN2 and MITF transcription factors in the initial induction and 
establishment of melanoma sphere growth states, we chose to examine two derived strains 
molecularly engineered from the melanoma sphere forming MM96L parental cell line.  We 
have previously described the MM96Lc8 and MM96Lc10 clonal derived lines that were 
established by permanent transfection and selection for expression of a BRN2 antisense RNA 
construct (Thomson et al., 1995).  Both of these cell lines were subsequently shown to 
consist of two subpopulations that differed morphologically in being dendritic (D) or low 
contrast (LC) under bright field microscopy, and which retained (D) or ablated (LC) the 
expression of the BRN2 and MITF proteins, as well as differentially expressing several 
pigmentation-associated antigens (Cook et al., 2006).  These clonal sub-variants 
MM96Lc8LC and MM96Lc10LC were used to assay the effect on melanoma sphere 
formation of the loss of the BRN2-MITF axis when compared with the MM96L parental and 
MM96Lc8D and MM96Lc10D cell lines (Figure 5A).   There was little difference between 
the parental and dendritic cell lines in the number, efficiency, appearance and propagation of 
the spheres generated when switched to hESCM-KSR media.   In disparity both of the low 
contrast cell lines generated melanoma spheres poorly, with MM96Lc8LC only able to 
generate small spheres, at an extremely low rate and over much longer time frames (several 
weeks).  The number of spheres forming 11 to 31 days post induction were quantitated by 
aspiration from the dish and the counts are presented in Figure 5A, where it is clear that 
MM96Lc10LC was also compromised in its melanoma sphere forming ability.   
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Each of these cell lines were tested in a 3D spheroid aggregate model where it was clear that 
the low contrast lines were also unable to adhere to each other and form a compact structure 
(Figure 5B).  Low contrast cells also had a reduced ability to produce outgrowths (invade) 
through a collagen matrix when propagated as melanoma spheres in comparison to the 
parental MM96L cell line with MM96Lc8LC showing no outgrowths (Figure 5C).  
Furthermore, testing of the protein expression profile of these cell lines grown in the adherent 
or melanoma sphere state revealed contrasting results (Figure 5D).  The loss of BRN2-MITF 
proteins was apparent in extracts prepared from the MM96Lc8LC and MM96Lc10LC cells 
as either adherent (lanes 5, 9) or as melanoma spheres (lanes 6, 10), as was the loss of the 
pigmentation markers TYRP1 and DCT.  The NOTCH pathway was again disturbed with the 
BRN2 ablated cells, containing higher levels of NOTCH1 which was not down regulated in 
the MM96Lc10LC melanoma spheres.  
Discussion 
The increased ability of a range of melanoma cell lines to form spheres in hESCM-KSR as 
compared to hESCM-FBS medium indicates that bovine serum may contain inhibitory 
factors preventing the cells from reacting to stem cell like conditions that may be enhanced 
during metastatic transformation (Mani et al., 2008).  FBS is known to contain growth 
factors promoting cell attachment as well as differentiation both of which may counteract 
sphere formation.  Another recent study has described the melanoma sphere forming ability 
of a single melanoma cell line WM-266-4, in which there was reported to be a small 
endogenous floating population of cells able to assume this state upon serum depletion and 
growth in neural stem cell-enriched media (Na et al., 2009a).  We have also tested this same 
cell line and found it to form spheres in both types of media using our conditions 
(Supplementary Table 1).  Notably, sphere formation of the WM-266-4 cell line could be 
promoted by treatment with a specific developmentally staged embryo extract from 
Zebrafish, possibly through TGF-β like signalling molecules (Na et al., 2009b).  Thus, 
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melanoma sphere formation is directly influenced by the microenvironment the cells are 
subjected to, with embryonic conditions stimulating the adoption of this state of growth and 
plasticity (Fang et al., 2005).  Switching from epithelial to mesenchymal cell states (EMT) is 
a major determinant of melanoma metastasis which results in altered cell adhesive, invasive 
and migratory properties (Alonso et al., 2007; Smit et al., 2007).  This is possibly linked to 
the changes in regulatory proteins accompanying the switch between melanoma cells grown 
in an adhesive or melanoma sphere states.  
A general characteristic of growth as melanoma spheres compared to their adherent growth 
pattern was the reduction in the levels of the transcription factors assayed including BRN2, 
MITF, NOTCH1 and the JAG2 and DLL1 ligands.  The NOTCH pathway participates in a 
variety of cellular processes including cell fate specification, proliferation, adhesion, 
migration and EMT, and more recently has been implicated in conferring a transformed 
phenotype when expressed in normal human melanocytes (Pinnix et al., 2009) and 
progression of melanoma to metastasis (Pinnix and Herlyn, 2007).  A link between the 
BRN2-MITF controlled gene network and regulation of the NOTCH pathway as seen with 
the reciprocal expression level changes upon repression of each molecule (Figure 4) has not 
previously been reported, but may have been anticipated.  BRN2 has been reported to 
interact with the proneural basic-helix-loop helix transcription factor Mash1 (Castro et al., 
2006).  This synergistic transcriptional activation occurs via an evolutionarily conserved 
octamer-E-box motif (termed the Mash1/Brn motif) first identified within the mouse Mash1-
specific enhancer of the Delta1 gene, which codes for one of several ligands for the Notch 
receptor.   Using a bioinformatics approach, the co-ordinate Mash1 ⁄ Brn motif could be 
identified in the promoters of 21 other genes, and which also included several other members 
of the Notch signalling pathway (Castro et al., 2006).  Thus BRN2 has been shown to 
interact with these elements and the presence of the E-Box that is a core element for the 
MITF target binding site means there are potentially two levels of interaction that may 
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regulate the NOTCH pathway in melanocytic cells.   The first is some direct BRN2-MITF 
joint interaction on the regulatory region of these genes to result in reciprocal expression 
patterns upon target sequence binding.  The other is a simple indirect mechanism whereby 
BRN2 levels are repressed with increasing MITF levels, thus reducing NOTCH pathway 
signalling through the absence of BRN2. 
There have been few reports directly examining the degree, nature and consequences of 
melanoma tumour heterogeneity and the variation of cell morphology and 
immunohistochemical patterns within single melanocytic lesions of patients (Ohsie et al., 
2008), this is surprising given a direct relationship of melanogenesis and differentiation 
status of melanoma cells (Houghton et al., 1987).  For reasons of simplicity the melanoma 
field has pursued the relative homogenous nature of stable cell clones in adherent culture.  
Melanoma cell lines do possess an innate ability to respond to extracellular cues provided by 
the ECM and associated signalling molecules, with phenotypic switching apparent when 
introduced into an embryonic microenvironment illustrating the plasticity of these cells 
(Hendrix et al., 2007).   A recent model of melanoma progression has been put forward by 
Hoek and colleagues (2008) in which there is epigenetic switching of the gene expression 
pattern of cells from a proliferative to an invasive signature (Hoek et al., 2008), moreover 
these are proposed to represent distinct yet interchangeable states which are regulated by 
signals from the microenvironment.  The existence of two separate states within melanoma 
tumour xenografts studied in this work (Hoek et al., 2008) was supported by histochemical 
staining for MITF and Ki67 antigens, which appeared higher in tumours derived from 
proliferative cell lines. 
This association of MITF with the proliferative gene expression pattern has recently been 
supported by the finding of two distinct heterogeneous subpopulations within melanoma 
tumour biopsies as being largely MITF positive or negative.  The more invasive fraction 
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being less proliferative and expressing low levels of MITF and high levels of p27Kip1 
(Carreira et al., 2006).  The ability of the BRN2 regulatory molecule (Cook and Sturm, 2008) 
to act as a direct repressor of the MITF gene promoter (Goodall et al., 2008), combined with 
the discovery that MITF and BRN2 can be expressed in different subpopulations of cells 
within melanoma tumours, has lead to the hypothesis that individual cells may switch 
between BRN2+/MITF- and BRN2-/MITF+ states depending upon the extracellular cues.  
Alternatively this could be based on a stochastic mechanism in the absence of any signal 
(Dodd et al., 2007), and that neither of these populations will reach clonal dominance within 
a tumour.   Finally, remarkable images have recently been obtained using intravital 
microscopy to demonstrate that migrating B16-GFP tagged melanoma cells within tumours 
contain little or no pigment and high levels of BRN2 promoter activity (Pinner et al., 2009), 
showing that it is a subset of undifferentiated melanoma cells that exit the primary tumour 
and give rise to the bulk of the resultant MITF positive differentiating cells during 
metastasis. 
We have shown that melanoma cells grown in the adherent state or as short term spheroid-
aggregates express high levels of both BRN2 and MITF unlike melanoma in situ.  Induction 
of melanoma sphere formation and growth as tumour xenografts restores in part the 
BRN2+/MITF- or BRN2-/MITF+ reciprocal cellular expression patterns as seen in human 
melanoma tumours (Figure 3) (Goodall et al., 2008).  Our results demonstrate the importance 
of a BRN2-MITF axis of gene expression in efficient melanoma sphere formation as ablation 
of BRN2 results in poor sphere formation, and as we previously demonstrated a lack of 
ability to establish of tumours in mouse xenografts (Thomson et al., 1995).  Thus the study of 
melanoma sphere formation should provide a useful approach to gain insight into the 
processes that induce metastasis of melanoma.  As a model, it is much more representative of 
melanoma in situ, and so potentially will provide more successful outcomes for novel drug 
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therapies than present models where results in vitro cannot be reproduced in the patient 
(Smalley et al., 2006). 
Materials and methods 
Melanoma monolayer, sphere cell culture and spheroid formation 
Human melanoma cell lines (listed in Supplementary Table 1) were maintained as a 
monolayer in MEL medium (RPMI 1640 medium supplemented with 2 % FBS, 3 % serum 
supreme, L- glutamine and pen strep).  Melanoma sphere growth was induced by placing 
roughly 2.5 x 105 cells in a T25 flask in one of three types of medium; MEL medium, mouse 
embryonic fibroblast-conditioned human embryonic stem cell (hESC-KSR) medium (Fang et 
al., 2005), or hESC-FBS medium (hESCM-KSR medium in which the Knockout Serum 
Supreme was replaced with 10 % FBS).  The cultures were allowed to grow for a minimum 
of 14 days with media changes every second or third day and melanoma sphere formation 
was determined by the presence of floating clumps of 5 or more living cells using contrast 
microscopy (Supplementary Table 1).  Floating spheres were passaged by mechanical 
disruption or enzymatic dissociation into single cell suspension and replated every 7-14 days.  
Adherent melanoma cells were induced to form 3D spheroid aggregates by liquid overlay 
onto Noble agar plates as described (Smalley et al., 2006). Harvested floating spheres or 
aggregates were each imbedded into a gel of bovine collagen-1 as previously described 
(Smalley et al., 2006) and left to invade in hESCM media for 72 hours. 
TaqMan real-time PCR assay and siRNA transfection of adherent melanoma cells 
Total cellular RNA was isolated and cDNA was prepared from monolayer and melanoma 
sphere cultures essentially as described (Smit et al., 2007) and used for quantitative RT-PCR. 
Melanoma spheres were collected by spinning down the media to avoid collecting adherent 
cells.  TaqMan probes for ABCB5 (Hs00698751_m1), BRN2 (Hs00271595_s1), DLL1 
(Hs00194509_m1), GAPDH (Hs99999905_m1), JAG2 (Hs00171432_m1), MITF 
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(Hs00165156_m1), and NOTCH1 (Hs01062014_m1) (Applied Biosystems) were used as per 
manufacturers instructions using 50 ng cDNA.  Data collection and analysis was performed 
using an ABI Prism 7500 (Applied Biosystems) with gene expression of averaged duplicate 
reactions normalized to either GAPDH or 18S ribosomal RNA.  
Custom siRNA molecules (Ambion) specific to BRN2 (Cook et al., 2005) and predesigned 
to MITF (No. 115142) (Newton et al., 2007) were used in conjunction with a commercial 
negative control sequence (No. 4611) to monitor off-target effects.  Transfections of MM96L 
cells were performed using 100 pmol of siRNA molecules using Lipofectamine 2000 and 
cells lysed after 48 hours as described (Smit et al., 2007). 
Protein analysis of cell extracts by Western immunoblot 
Total cell extracts were collected from melanoma spheres and 80% confluent monolayer 
cultures and used for western immunoblotting as described previously (Cook et al., 2003).  
Membranes were incubated with primary antibody for 1 hour at room temperature or 
overnight at 4° C at the following dilutions in 5% skim milk; anti-BRN2 1:500 (Smith et al., 
1998), anti-MITF 1:50 (Sigma), anti-NOTCH1 1:1000 (Sapphire Bioscience), anti-DLL1 
1:500 (Sapphire Bioscience), anti-JAG2 1:1000 (Cell Signaling), and anti-glyceraldehyde-3-
phosphate dehydrogenase 1:20000 (R&D Systems) as the loading control. The appropriate 
HRP-conjugated secondary antibody diluted in 3% skim milk 1:8000 to 1:10000 (ZyMed) 
was incubated with membranes for 1 hour at room temperature and membranes were 
visualized using Immobulin Western (Millipore). 
Immunofluoresence microscopy 
Melanoma spheres were collected and rinsed in PBS twice before incubation in 4% 
paraformaldehyde for 1 hour at room temperature.  After two rinses in PBS, the spheres were 
embedded in O.C.T. (Tissue-Tek) and cut into 10 µm sections using a Leica cryostat 
CM3050 S.  Cells were permeabalised by incubation in 0.1 % Triton X for 10 min, rinsed in 
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0.5 % BSA in PBS 2 x 10 min, and incubated with primary antibody overnight at 4° C. 
Antibodies were used at the following dilutions, BRN2 1:50, MITF 1:50, NOTCH1 1:100, 
JAG2 1:100, and DLL1 1:100 were all diluted in 0.5 % BSA in PBS, except for xenograft 
samples for which a M.O.M. blocking kit  was utilised (Vector Laboratories, Cat# BMK-
2202) as per instructions.  After 3 x 10 min washes in 0.5 % BSA in PBS, sections were 
incubated in corresponding anti-rabbit or anti-mouse Alexa Fluor 594- or 488-conjugated 
secondary antibody 1:200 for 1 hour at room temperature and again washed 3 x 10 min 0.5 % 
BSA in PBS.  Finally, the sections were incubated in DAPI 1:1000 for 10 min and staining 
was observed using confocal microscopy and standard fluorescence microscopy.  Monolayer 
cells were plated on glass coverslips, fixed in 4% paraformaldehyde and stained as described 
previously using the same antibody dilutions as above (Cook et al., 2003). 
Mouse xenografts, human tissue samples, antigen retrieval, and H&E staining 
Attached melanoma cells were harvested by enzymatic digestion and melanoma spheres were 
pelleted from the media and washed in PBS.  Matched adherent and sphere preparations were 
injected into the left and right flank, respectively, of 4 week old NOD/SCID IL2g-/- mice.   
Five mice per group were injected intradermally with 200,000 or 20,000 cells in 100 μl of 
Matrigel per injection site.  The mice were sacrificed in groups according to when one mouse 
in each group yielded a tumour size of 0.5 cm3.  Tumours were excised, fixed in formalin, 
transferred to ethanol then embedded in paraffin.  Blocks were processed for staining and 
antibody binding as per below. 
Primary human superficial spreading melanoma tissues removed from a 78 year old with a 
facial lesion were obtained as formalin-fixed, paraffin-embedded blocks and cut as serial 
whole 10μm transverse cross sections (Richmond-Sinclair et al., 2008).  Sections were 
deparaffinised in xylene and rehydrated in an ethanol gradient prior to antigen retrieval.  
These were heated to 125 degrees Celsius, for 4 min in a 10mM citrate buffer pH 6.0 (Vector 
Laboratories, cat# H-3300) using an antigen decloaking chamber (Biocare Medical Model# 
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DC2002).  The sections were then microwaved (600W) twice, for 8 min each, with a fresh 
citrate buffer change between heating cycles, then cooled to room temperature prior to 
antibody labeling.  10μm tumour serial sections were deparaffinised in xylene, rehydrated in 
an ethanol gradient series, treated with hemotoxylin for 3 min, rinsed in concentrated HCl, 
partially dehydrated in ethanol, treated with eosin for 20 sec and dehydrated in an ethanol 
gradient series prior to being mounted with Entellan (Pro Sci Tech cat# IM022).  All 
experiments were undertaken with the approval of the University of Queensland research 
ethics committee. 
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Figure legends 
Figure 1.  Melanoma sphere induction in human melanoma cell lines.   A and B.  A11 
and D10 cell lines were plated as adherent monolayers and grown to confluence in T75 flasks 
before changing to the media indicated above the panels as MEL, hESCM-FBS or hESCM-
KSR.  Digital pictures were taken of cells under bright field microscopy on the days as 
indicated to the right of the panels (D4, D6, D9, D13).  Floating cell aggregates were 
harvested from the flasks at D14 or earlier and passaged as melanoma spheres as described.  
Scale bars in black represent 200 microns.  C.  Loss of pigmentation in A11 melanoma cells 
was apparent upon changing from adherent to detached growth states.  The colour of the cell 
pellets from adherent cells (P0) and those from serially passaged melanoma spheres in 
hESCM-KSR medium (P1, P2, P3) demonstrates the cells becoming amelanotic. 
Figure 2.  Regulatory protein changes between adherent and melanoma sphere cell 
growth.  A. Individual western blot filters of total protein lysates prepared from A2058 
(lanes 1, 2), A11 (lanes 3, 4) and MM96L (lanes 5, 6) cell lines grown as adherent (A) or 
melanoma spheres (S) were probed with the antibodies indicated to the left of each panel.   
The loading control was GAPDH.  B.  Quantitative RT-PCR was performed on total RNA 
extracted from adherent (A) or melanoma spheres (S) to determine the expression level of 
BRN2, MITF, NOTCH1, JAG2, DLL1 and ABCB5.  Levels were normalized to GAPDH and 
plotted as histograms in relative expression units, with the bars showing the range of 
expression.  C.  A2058 cells grown as adherent or as melanoma spheres were either fixed on 
cover slips or prepared as sections respectively.  Immunofluorescence microscopy was 
performed on these samples using antibodies to NOTCH1, JAG2 and DLL1 proteins as 
indicated above the panels.  The blue DAPI stain highlights the nucleus of each cell.  A 
difference in JAG2 expression intensity relative to the DAPI stained nuclei can be seen in the 
centre panel.  Scale bars in white represent 20 microns. 
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Figure 3.  Heterogeneous BRN2 and MITF expression patterning in melanoma and 
melanoma models.  A. Immunofluorescence microscopy of BRN2 (red) and MITF (green) 
costained adherent cells, agar spheroid aggregates and melanoma spheres in three different 
cell lines, A2058, A11 and MM96L.  Spheroid aggregates and spheres were fixed in 4% 
PFA, imbedded in OCT thermal compound, cryosectioned and antigen retrieved prior to 
labelling with antibody.  Scale bars in white represent 100 microns.  B. Immunofluorescent 
BRN2 (red) and MITF (green) costaining of human cell lines WM3437 and WM115 induced 
to grow as melanoma tumour xenografts on the flanks of immunocompromised mice.  H&E 
histology stains were conducted to gain structural and morphological context were cut in 
serial section from samples presented for immunofluorescence.  Scale bars in white represent 
100 microns.  C. Immunofluorescent BRN2 (red) and MITF (green) costaining of a human 
primary facial superficial spreading melanoma.  The tumour was surgically removed, 
formalin fixed, paraffin imbedded, sectioned at 10μM, and antigen retrieved prior to antibody 
labelling.  Scale bars in white represent 500 or 100 microns (zoomed section).  The region 
presented at greater magnification is boxed. 
Figure 4.  Gene expression patterns upon BRN2 and MITF repression and melanoma 
sphere formation.  A and B.  Cultures of MM96L and A2058 grown as adherent cells were 
separately treated with siRNA directed against BRN2 (B), MITF (M) and a negative control 
sequence (C), 48 hours later cells were assessed for the expression of the genes indicated 
above each graph by quantitative RT-PCR with levels normalised relative to 18S RNA.  C.  
Total protein extracts from the same siRNA treated cells as indicated in parts A and B were 
subject to western immunoblot with the antibodies indicated to the left of each panel, 
GAPDH serving as the loading control.    
Figure 5.  Ablation of BRN2 inhibits sphere formation and invasion, and alters the 
expression of downstream targets.  A.  Melanoma spheres at 31 days post induction are 
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shown with the field representative of a random 5% of the area occupied by the total spheres 
per cell line over this time period.  Sphere count contained in a 100μl aliquot of low speed 
pelleted media per cell line.  After observing sphere formation and density by light 
microscopy spheres were counted at days 11, 13 and 15 for clone 10 and days 25, 27 and 29 
for clone 8.  Scale bars in black represent 200 microns.  B. Agar spheroid bright field light 
microscopy images (4X objective) at 72 hours post induction.  Scale bars in black represent 
200 microns.  C. Sphere cells invading though collagen (4X objective).  Spheres were 
imbedded in collagen and incubated for 72 hours in hESCM media.  MM96L parent line 
shows good outgrowth of cells from the sphere, with little outgrowth observed for the low 
contrast MM96Lc10LC (10LC) and no outgrowth for the MM96Lc8LC (8LC) clones.   Scale 
bars in black represent 100 microns.   D. Total protein lysates prepared from MM96L 
parental (P) (lanes 1, 2), MM96Lc8D (lanes 3, 4), MM96Lc8LC (lanes 5, 6), MM96Lc10D 
(lanes 7, 8) and MM96Lc10LC (lanes 9, 10), with cell strains grown as adherent (A) or 
melanoma spheres (S), were probed with the antibodies indicated to the left of each panel.  
GAPDH was used as a loading control.  
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